By Sabela Ojea

The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.

The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

May 23, 2023 18:55 ET (22:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Innoviva.
Innoviva (NASDAQ:INVA)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Innoviva.